Pompe
82 programs · 79 companies
Programs
82
Companies
79
Trials
68
MOAs
46
TYK2iFXIaiCD3xCD20FcRniPD-L1iGLP-1agBCL-2iPRMT5iWEE1iMALT1i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisonaritide | Phase 3 | IL-13 | ||
| BMY-9931 | Phase 1 | GPRC5D | ||
| SNY-8628 | NDA/BLA | B7-H3 | ||
| Zorizanubrutinib | Phase 1 | BTK | ||
| Suracagene | Phase 3 | PRMT5 | ||
| Motainavolisib | NDA/BLA | CD47 | ||
| MRN-7601 | Phase 2 | IL-13 | ||
| HAL-996 | Phase 1/2 | BCL-2 | ||
| ASN-4879 | Phase 3 | CGRP | ||
| Motanaritide | Approved | PD-1 | ||
| CRS-184 | Phase 1/2 | AHR | ||
| RCU-8819 | Preclinical | B7-H3 | ||
| Nidasacituzumab | Phase 3 | TIGIT | ||
| ITO-535 | NDA/BLA | MDM2 | ||
| Rimatinib | Phase 1 | CD20 | ||
| Polazumab | Phase 2/3 | IL-13 | ||
| Liralucimab | Phase 2 | AHR | ||
| Riboderotide | Phase 2 | PSMA | ||
| Mavulucimab | NDA/BLA | AHR | ||
| 600-1653 | NDA/BLA | GLP-1R | ||
| SUN-5027 | Preclinical | DLL3 | ||
| Doxafotisoran | NDA/BLA | TIM-3 | ||
| Zenorasimod | Phase 2 | PRMT5 | ||
| TEM-8322 | Preclinical | IL-23 | ||
| NCI-IIT-608 | NDA/BLA | WRN | ||
| SEO-IIT-337 | Phase 1/2 | WRN | ||
| SEA-4335 | Phase 3 | PARP | ||
| Adagracapivasertib | Approved | MALT1 | ||
| Zorinesiran | Phase 2/3 | JAK2 | ||
| ZNT-6525 | Phase 1 | CDK2 | ||
| Rimanesiran | Phase 1 | EZH2 | ||
| ACI-6417 | Phase 2/3 | HER2 | ||
| Kemalemzoparlimab | Phase 2 | WEE1 | ||
| Geliglumide | Phase 1 | PI3Kα | ||
| INH-2936 | Phase 2 | PD-L1 | ||
| CLR-3690 | Phase 3 | RET | ||
| EYE-7734 | Phase 1 | KRASG12C | ||
| Pemiratamab | Phase 2/3 | TYK2 | ||
| NUW-823 | Phase 1 | SGLT2 | ||
| Capibrutinib | Phase 3 | APOC3 | ||
| Kemamavacamten | Preclinical | AHR | ||
| Mirilemzoparlimab | Phase 2 | CD20 | ||
| 302-9165 | Approved | PSMA | ||
| Ivorasimod | Approved | PD-1 | ||
| CAR-9528 | Preclinical | SOS1 | ||
| ASK-6688 | NDA/BLA | SGLT2 | ||
| Suraglumide | Phase 1 | MALT1 | ||
| ENC-4310 | Phase 1/2 | TROP-2 | ||
| ALD-7113 | Phase 3 | RET | ||
| Cevifutibatinib | Phase 1 | BCL-2 | ||
| Mavuinavolisib | NDA/BLA | SHP2 | ||
| ADA-3632 | NDA/BLA | BET | ||
| Rimacilimab | Phase 3 | USP1 | ||
| Elralemzoparlimab | Phase 1/2 | IL-13 | ||
| Teraglumide | Phase 2 | BCMA | ||
| GNL-2086 | Preclinical | CD3 | ||
| Darafutibatinib | NDA/BLA | GPRC5D | ||
| DAI-6285 | Phase 1/2 | BET | ||
| Gozecilimab | Phase 2 | SMN2 | ||
| Lisosacituzumab | Phase 1/2 | LAG-3 | ||
| STA-5151 | Phase 1/2 | Tau | ||
| MRE-2348 | Preclinical | FXIa | ||
| Mavutenlimab | Phase 2 | EGFR | ||
| 414-2764 | Phase 2/3 | Tau | ||
| Talanesiran | Preclinical | PLK4 | ||
| Gozesertib | Phase 1/2 | CDK2 | ||
| MIN-2764 | Phase 3 | PCSK9 | ||
| Polaratamab | Phase 2 | FLT3 | ||
| DIV-7153 | Preclinical | TIM-3 | ||
| Talafutibatinib | Phase 3 | TROP-2 | ||
| JUB-6434 | Phase 1 | MDM2 | ||
| Ceviglumide | Phase 3 | IL-17A | ||
| HYP-6990 | Preclinical | PI3Kα | ||
| AIP-1890 | Phase 3 | DLL3 | ||
| AII-IIT-727 | Phase 2/3 | SGLT2 | ||
| KIN-IIT-300 | Phase 2/3 | PARP | ||
| KIN-IIT-556 | Approved | CD20 | ||
| Polalemzoparlimab | Phase 1 | WEE1 | ||
| ATA-3814 | NDA/BLA | CD20 | ||
| Kemacapivasertib | Phase 2/3 | MDM2 | ||
| Miriosocimab | Approved | DLL3 | ||
| AMY-7629 | Phase 2/3 | KIF18A |
Trials (68)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT04357174 | SNY-8628 | NDA/BLA | Active |
| NCT06026756 | Zorizanubrutinib | Phase 1 | Completed |
| NCT08753632 | Zorizanubrutinib | Phase 1 | Terminated |
| NCT05887547 | Suracagene | Phase 3 | Completed |
| NCT06642700 | Suracagene | Phase 3 | Completed |
| NCT05616115 | Motainavolisib | NDA/BLA | Completed |
| NCT04810456 | CRS-184 | Phase 1/2 | Recruiting |
| NCT06963354 | ITO-535 | NDA/BLA | Recruiting |
| NCT07833768 | Polazumab | Phase 2/3 | Active |
| NCT06059710 | Liralucimab | Phase 2 | Recruiting |
| NCT03977112 | Mavulucimab | NDA/BLA | Active |
| NCT05114101 | 600-1653 | NDA/BLA | Terminated |
| NCT05657890 | Doxafotisoran | NDA/BLA | Recruiting |
| NCT03871867 | NCI-IIT-608 | NDA/BLA | Completed |
| NCT07205877 | SEO-IIT-337 | Phase 1/2 | Completed |
| NCT03243895 | SEA-4335 | Phase 3 | Terminated |
| NCT05341929 | SEA-4335 | Phase 3 | Terminated |
| NCT03055788 | Adagracapivasertib | Approved | Completed |
| NCT08150402 | Zorinesiran | Phase 2/3 | Not yet recr... |
| NCT05069648 | Rimanesiran | Phase 1 | Recruiting |